Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, et al. Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy. Lancet Oncol 2025;26:e332-e333.
PMID: 40609573